regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Education == Robinson received her Bachelor of Arts degree in biology from Smith College in Massachusetts. She completed her PhD at Harvard University supervised by David Albertini and also Barbara Pearse. In 2003 she was appointed Professor of Molecular Cell Biology at the Cambridge Institute for Medical Research and is conducting research on coated vesicle proteins. Margaret Robinson was first exposed about science early in her life from reading about Marie Curie. While enrolled at Smith College, she planned on being an English or theater major. However, due to university requirements, Margaret had to complete an introductory biology course. In that course, Jeanne Powell gave a lecture on cells and showed her students electron micrographs. This is when Margaret really became interested in cellular biology; the complexity of cells intrigued her. After receiving her undergraduate degree, Robinson took a year off and ended up at Harvard Medical School. Robinson eventually joined a new lab and was able to conduct research on anything she liked. Due to her inexperience, her research did not go as planned and was nearly kicked out of graduate school. Robinson had to stop working on her interest in coated vesicles and work on something closer to what the lab was researching. Robinson eventually started a postdoctoral research with Barbara Pearse, joining her at the MRC Laboratory of Molecular Biology in December 1982. Her interest was in clathrin-coated vesicles that binds to cargo.
bumping A phenomenon in which a homogeneous liquid raised to its boiling point becomes superheated and, upon nucleation, rapidly boils to the gas phase, resulting in a violent expulsion of the liquid from the container; in extreme cases, the container itself may shatter. Frequent stirring, the use of an appropriate container, and the use of boiling chips can help prevent bumping.
For services to Further Education and Skills Michael Davidson. Volunteer and Trustee, Royal Ulster Constabulary George Cross Foundation. For Voluntary Service. Janet Ann Davies. Councillor, Denbighshire County Council. For services to Local Government, to the NHS and to the community in Rhuddlan, Denbighshire. Jean Carol Davies. Chair and Coach, Saints Netball Club, Truro. For services to Netball and to the community in Cornwall. Dr Robert Havard Davies. Doctor, Neuro-Development Team, Betsi Cadwaladr University Health Board. For services to the NHS. Francisco Domingo Davila Davila. For services to the community in Wymondham, Norfolk. Brendan William Davis. Head of Operations, Government Car Service. For services to Government and Major Events. Rachel Frances Davis. For services to the community in Cranford, Northamptonshire. Audrey Dempsey. Founder, Glasgow's No1 Baby and Family Support Service. For services to Families and Vulnerable People in Glasgow. Janet Mary Dicks. For services to the community in Hadleigh, Suffolk. Ann Doreen May Doody. For services to the community in Ilfracombe, Devon. Trevor Samuel John Douglas. General Manager, Belfast Cathedral. For services to Peacebuilding and to the community in Northern Ireland. Lee William Doyle. Chief Executive Officer, Brentford FC Community Sports Trust. For services to Sport and to the community in Brentford, London Borough of Hounslow. Janet Shirley Dyer. Catering Manager, National Fire Service College. For services to the community in Moreton-in-Marsh, Gloucestershire. Patricia Carol Earl.
=== Laboratory Analysers === Automated analysers, by the association of robotics and spectrophotometry, have allowed these last decades better reproducibility of the results, in particular in medical biochemistry and hematology. Efficiency and productivity can be enhanced by automating the pre-analytical processing, including barcode reading, sorting, centrifuging, and aliquoting specimens. The analysers must undergo daily controls prior to performing patient testing. Analysers must also undergo daily, weekly and monthly maintenance. Quality management involves reviewing quality control trends to detect emerging problems in instrument calibration, correlating results between instruments that perform similar testing, and running standardized samples to prove linearity and precision. Some laboratory processes involve automated analysis combined with manual review by technologists. For example, when hematology analysers flag samples as abnormal, automated white blood cell differential counts may be superseded by manual differential counts using stained slides read at the microscope or scanned by digital imaging software. Laboratory technologists may flag abnormal samples for pathologist review. The pathologist may recommend additional testing, such as flow cytometry to identify lymphoma or leukemia cells, or cytology to characterize solid tumor cells.
Sources: en.wikipedia.org
=== Legal status === In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Nexviadyme, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Genzyme Europe BV. In August 2021, Genzyme Europe BV requested a re-examination. Avalglucosidase alfa was approved for medical use in the European Union in June 2022. The U.S. Food and Drug Administration (FDA) granted the application for avalglucosidase alfa fast track, priority review, breakthrough therapy, and orphan drug designations. The FDA granted the approval of Nexviazyme to Genzyme Corporation.
On November 12, 2024, President-elect Donald Trump named Hegseth as his nominee for secretary of defense, after Arkansas senator Tom Cotton announced he would not serve as secretary. Hegseth subsequently ended his contract with Fox News. The selection of Hegseth was seen as a sign that Trump sought to appoint a loyalist to lead the Department of Defense, and his relative lack of experience surprised officials in the department. According to Vanity Fair, Trump's transition team became aware the following day of a sexual assault allegation involving Hegseth that occurred in Monterey, California, seven years prior; The Washington Post reported that senior officials on the team were surprised by the allegation and reconsidered his nomination. Despite the allegation, Trump defended Hegseth and several Republican senators indicated that they would support him. His nomination was threatened by an article from Jane Mayer in The New Yorker detailing alleged financial mismanagement and alcohol issues while leading his veterans' groups, while an NBC News article reported that his drinking habits concerned his colleagues at Fox News; The New York Times reported in December that Trump had begun to consider Florida governor Ron DeSantis as an alternative. In an effort to retain his nomination amid controversies, Hegseth began a campaign that month. Advisors to Trump privately sought to persuade him to support Hegseth in fear that it would embolden recalcitrant Republican senators, while he could not garner support for DeSantis, according to The New York Times.
Like other AASs, oxandrolone is an agonist of the androgen receptor, similar to androgens such as testosterone and DHT. The relative binding affinity of oxandrolone for the androgen receptor is about 0.3% of that of metribolone. Activation of the androgen receptor stimulates protein synthesis, which increases muscle growth, lean body mass, and bone mineral density. Compared to testosterone and many other AASs, oxandrolone is less androgenic relative to its strength as an anabolic. Oxandrolone has as much as six times the anabolic potency of testosterone and has significantly reduced androgenic potency in comparison: oxandrolone exhibits significantly lower virilizing androgenic properties compared to testosterone, with a relative androgenic potency of only 5%. Compared to methyltestosterone, oxandrolone has about 322 to 633% of the anabolic potency and 24% of the androgenic potency. The reduced ratio of anabolic to androgenic activity of oxandrolone motivated its medical use in children and women because less androgenic effect implies less risk of virilization. The bodybuilding community also considers this fact when choosing between AASs. As of 2003 and 2011 Oxandrolone was thought to be "uniquely" far less hepatotoxic than other 17α-alkylated AASs, which was thought to be due to differences in metabolism. This turned out not to be the case in the long run, which is why it was taken off the US market in 2023.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.